secwatch.observer — SEC 8-K summary
======================================

Issuer:     PALATIN TECHNOLOGIES INC (PTN)
CIK:        0000911216
Form:       8-K
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0001654954-25-003600
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Palatin reports positive Phase 2 topline results for UC drug PL8177 and obesity combo study
--------------------------------------------------------------------------------

- UC Phase 2: Clinical remission 33% PL8177 vs 0% placebo; clinical response 78% vs 33% (p<0.005) after 8 weeks.
- Obesity Phase 2: Co-admin bremelanotide + tirzepatide met primary endpoint with 4.4% weight loss vs 1.6% placebo (p<0.0001).
- Obesity: 40% of co-admin group achieved 5% weight loss (p<0.05); low-dose bremelanotide stopped weight regain post-tirzepatide.
- Next-gen MC4R long-acting peptides and oral small molecules; IND applications planned for 4Q25, clinical data 1H26.
- Licensing discussions for UC program advancing with multiple big pharma companies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/911216/000165495425003600/0001654954-25-003600-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/911216/000165495425003600/ptn_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-25-003600

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer